Volume 18, Number 1 Winter Newsletter March, 2019

Abstracts for the Orlando ACS Meeting Available for

Download Soon! Scientific Program for the 257th ACS Meeting,
Orlando, FL (Mar 31-Apr 4, 2019)
Abstracts for the upcoming Orlando ACS meeting will (ACS Abstract system now closed for this meeting)
soon be available on the Division web site. Follow the SUN AM Small Molecule Immunomodulators in Cancer
link below for the MEDI abstracts: SUN AM General Oral Session I
SUN PM Protein Degraders
www.acsmedchem.org/?nd=nationalmeetings SUN PM General Oral Session II
SUN EVE Poster Session I and Social Hour
Quick Reference Guide to Services MON AM Synthetic Technologies
MON AM Therapeutic Developments in Health Disparities
Division Web Site: www.acsmedchem.org MON PM Small Molecule Therapeutics for Neuro-oncology
MON PM Besides Off Rate: On Rate and Rebinding
Division Hall of Fame: MON EVE SCI-MIX
www.acsmedchem.org/?nd=hof TUES AM Awards Session
TUES AM Recent Advances in Targeting KRAS
TUES PM Ions Count: Acids, Bases, Zwitterionics
Division Awards and Prizes
TUES PM Academic Drug Discovery
www.acsmedchem.org/?nd=awards WED AM First Time Disclosures
WED AM Exploring Cryptic Pockets
Link to Division Newsletter Archive: WED AM Covalent Inhibition Beyond Cysteine
www.acsmedchem.org/?nd=newsletters WED PM First Time Disclosures
WED PM General Oral Session III
Link to Archived MEDI Meeting Abstracts: WED PM Target (In)Validation--Early Discovery
www.acsmedchem.org/?nd=nationalmeetings WED EVE Poster Session II & Social Hour (w/ORG)

ACS Web Page Scientific Program for the 258th ACS Meeting, San
portal.acs.org Diego, CA (Aug 25-29, 2019)
(ACS Abstract system open now, maps.acs.org)
SUN AM Machine Learning in Med Chem
Journal of Medicinal Chemistry SUN AM General Oral Session I
pubs.acs.org/journal/jmcmar SUN PM Disease-Modifying Approaches to
Neurodegeneration
SUN PM General Oral Session II
2019 Executive Committee Members SUN EVE Poster Session I and Social Hour
MON AM Emerging Women in Medicinal Chemistry
MON AM Approaches to NAFLD/NASH
2019 Chair: Andrew W. Stamford
MON AM Catastrphic Epilepsies
2019-2020 Program Chair: Jacob Schwarz MON PM Therapeutic Agents for Chronic HBV
2019 Vice-Chair: Scott Runyon MON PM No Linker Required: Non-PROTAC Degraders
Industrial Councilor 2019-21: Amy Ripka MON PM Optimizing Brain Penetration
Industrial Councilor 2018-20: William J. Greenlee MON EVE SCI-MIX
Academic Councilor 2017-19: Jane Aldrich TUES AM Awards Session
Academic Councilor 2018-20: Carrie Haskell-Luevano TUES AM Drug Discovery Beyond the Rule of 5
Secretary/PR Chair 2017-19: D. Eric Walters TUES PM Awards Session
TUES PM Privileged & Underprivileged Functional Groups
Membership & Intl. Chair: Daniel Harki
WED AM First Time Disclosures
Treasurer 2018-20: David P. Rotella WED AM Emerging Targets for Drug Abuse Therapy
2019 Past Chair: Paul Ornstein WED PM First Time Disclosures
WED PM General Oral Session III
Contact information for all Division Officers appears WED EVE Poster Session II & Social Hour (w/ORG)
at the end of this Newsletter.
 John Macor to Receive Smissman Award

The American Chemical Society Division of Medicinal

Chemistry is pleased to announce that Dr. John E. Macor has been
selected as the 2019 recipient of the Edward E. Smissman Award,
Sponsored by the Bruce E. and Cynthia A. Maryanoff Endowment
Fund.
This award is given to a living scientist whose research,
teaching or service has had a substantial impact on the intellectual
and theoretical development of the field of Medicinal Chemistry. Dr.
Macor will receive the award and give the award address at the 258th
National American Chemical Society Meeting in San Diego, CA, on
Tuesday, August 27.
Dr. Macor earned his B.S. degree from the University of Notre
Dame in 1982 doing undergraduate research with Professor Marvin Miller, and earned his Ph.D. degree
in organic chemistry at Princeton University with Professor E. C. Taylor (1986). Dr. Macor’s career has
spanned four different decades and four different pharmaceutical companies with significant
contributions in each of them. He began his career at Pfizer (Groton, CT) in 1986 where he was
engaged in a variety of CNS drug discovery efforts, moved to Astra Arcus (Rochester, NY) in 1994
focusing on cholinergic drug discovery, and then moved to Bristol-Myers Squibb in 1997 (Princeton, NJ),
starting in cardiovascular and moving to neuroscience in 2001 and immunosciences in 2013. He
assumed the role as Executive Director of Neuroscience Discovery Chemistry in 2002 (Wallingford, CT),
and he was appointed Executive Director of Immunosciences Discovery Chemistry (2013, Lawrenceville,
NJ). In October 2016, he accepted the role as Global Head of Integrated Drug Discovery for Sanofi with
groups in Paris, Frankfurt and Waltham, MA.
Dr. Macor was a co-inventor of Relpax® (eletriptan), an anti-migraine agent during his time at
Pfizer. He also discovered CP-93,129, a literature standard 5-HT1B receptor selective agonist, and CP-
122,288, a 5-HT1B/1D agonist that help to confirm the vascular mechanism-of-action of the triptans. While
at Astra, he was co-inventor of AZD0328, the first brain-penetrant, selective, full agonist for the α7
neuronal nicotinic receptors, which advanced to Phase 2 trials for schizophrenia. At Bristol-Myers Squibb
he led teams and was a co-inventor that discovered BMS-346567 (sparsentan, a dual AT1/ETA receptor
antagonist presently in Phase 3 clinical trials for focal segmental glomerulosclerosis [FSGS], a rare kidney
disease), BMS-708163 (avagecestat, a g-secretase inhibitor for Alzheimer’s Disease that demonstrated
b-amyloid lowering in the cerebral spinal fluid of normal healthy volunteers in a Phase 1 clinical study),
and BMS-927711 (rimegepant), a potent CGRP receptor antagonist for the treatment of migraine active
presently awaiting NDA submission. Dr. Macor and his teams have moved more than a dozen
compounds into clinical trials, including LX9211 (AAK1 inhibitor, neuropathic pain) and BHV-3500 (CGRP
antagonist, migraine) both presently in Phase 1.
Dr. Macor has authored/co-authored over 190 peer-reviewed publications, is an inventor on
more than 110 granted US patents, given more than 100 invited lectures, and has over 500 publications,
issued US patents, invited lectures and external meeting presentations. His contributions in the syntheses
of heterocyclic compounds, intramolecular 1,2,4-triazine Diels-Alder reactions, indole chemistry, and
conformation restriction using heterocycles as bioisosteres in medicinal chemistry are widely cited in the
literature. He has participated in and led teams in cardiovascular, metabolic, neuroscience, oncology
and inflammation projects, indicative of broad expertise, creativity and impact in medicinal chemistry
and drug discovery. Dr. Macor chaired the 2002 Gordon Research Conference on Medicinal Chemistry
and the 2006 Gordon Research Conference on Heterocyclic Compounds. Dr. Macor served as Editor-
in-Chief of Annual Reports in Medicinal Chemistry for Volumes 42 – 46 (2006 – 2011). Dr. Macor was
awarded the 2009 Scarborough Award in Medicinal Chemistry for medicinal chemistry
accomplishments under the age of 50, and was made an American Chemical Society Fellow in 2011.
Dr. Macor served as Chair of the Medicinal Chemistry Division (MEDI) of the American Chemical Society
in 2015 and served a total of ten years on the Executive Committee of MEDI in various roles. Dr. Macor
was awarded the 2014 Alfred Burger Award in Medicinal Chemistry (a National Award from the
American Chemical Society) to “to recognize outstanding contributions to research in medicinal
chemistry,” and was inducted into the Medicinal Chemistry Hall of Fame in August 2014.
 3 Clicks to Done
Analyze and identify samples in seconds

1 Import raw NMR data into 2 Propose a structure

ACD/Spectrus Processor*
OH
*All other analytical data (LC/UV/MS, IR,
Raman, and more) can also be processed in HO O
OH
the same interface

OH
HO

3
Peak Picking
Integration
Verify Multiplet Assignment
Instant Structure Verification

Results Evaluate your results, generate

multiplet reports, and start
planning your next reaction 0.96
17 OH
19 20

HO 3 O
HO O
OH

OH 7 9 18 OH
21
OH
HO

6 10
12 OH
13
HO
8

Fast-track your NMR analysis with ACD/Spectrus Processor

Register for the Webinar

March 7 th 10:00 AM EST
Years
https://bit.ly/2SWSitS
 Craig Lindsley Wins 2019 Robert M. Scarborough Award for
Excellence in Medicinal Chemistry

The Division of Medicinal Chemistry is pleased to announce that

Dr. Craig W. Lindsley has been selected as the recipient of the 2019
Robert M. Scarborough Award for Excellence in Medicinal Chemistry. This
award is intended to recognize individuals who have had primary,
leading roles in the discovery of novel therapeutic agents or who have
otherwise made significant scientific discoveries that enhance the field of
medicinal chemistry. It was named in memory of Robert M. Scarborough,
an accomplished medicinal chemist and inventor of drugs such as
Natrecor® and Integrilin®. The award is sponsored by Portola
Pharmaceuticals, Inc., a cardiovascular company founded by Dr.
Scarborough.
Craig W. Lindsley, Ph.D. is the Co-Director and Director of
Medicinal Chemistry for the VCNDD and University Professor of Pharmacology, Chemistry & Biochemistry
and holds the William K. Warren, Jr. Chair in Medicine. Craig graduated in 1992 from Cal State Chico
with a B.S. in Chemistry, received his Ph.D. degree in Chemistry from UC, Santa Barbara (Lipshutz), in
1996, and pursued postdoctoral studies at Harvard University. In 2001, Craig accepted a position at
Merck & Co where he pioneered the development of allosteric ligands, providing proof-of-concept
compounds and 6 clinical candidates. In 2006, Craig accepted an Associate Professor position at
Vanderbilt University, and was promoted to Full Professor in 2009, while serving as the founding Editor-in-
Chief of ACS Chemical Neuroscience. The following year, Craig was awarded the Portoghese
Lectureship from the ACS MEDI division, and in 2014, received the John J. Abel Award in Pharmacology
from ASPET. More recently, Craig was inducted as an AAAS Fellow, named a Thomson Reuters Highly
Cited Researcher (2015-2017) and Thomson Reuters World’s Most Influential Scientific Minds (2016). In
2018, Craig was honored as the 22nd Smissman Memorial Lecturer and co-founded Appello
Pharmaceuticals. Craig holds over 84 issued US patents and has published over 400 manuscripts.

Join MEDI on social media!

@ACSMEDI on Instagram and Twitter

Facebook: https://www.facebook.com/ACSMediDivision/

LinkedIn: https://www.linkedin.com/company/acsmedi/
Drug Discovery with Delivering
computational chemistry
to cheminformatics
®

High-level project management

Track and manage the entire drug discovery
process through LiveDesign by centralizing all
data and ideas in one place without having to
coordinate files, emails, or annotations and
enabling teams to effortlessly manage projects.

Accelerate project progression

LiveDesign’s web-based interface streamlines the
design process, allowing the entire project team
to work cooperatively and facilitating rapid
iterations of the design cycle.

Maximize modeling benefits

Access high-powered computational modeling with
the click of a button alongside informatics data,
empowering swift analysis and offering insights for
further improvements.

Seamless integration
LiveDesign is completely agnostic with the ability to
integrate with third-party and existing systems,
providing the means for full customization to suit
the needs of the project.

Learn more about how LiveDesign is accelerating drug

discovery processes worldwide
See LiveDesign in action at
Attend our talk at ACS Orlando: our ACS Orlando booth: #502
Delivering computational chemistry to cheminformatics:
collaborative drug discovery with LiveDesign Visit our website:

presented by Dr. Erin Davis

Session: CINF: Web-based Cheminformatics Platforms
Location: West Hall B4 - Theater 10, Orange County Convention
Center
www.schrodinger.com/livedesign
Date and Time: Tuesday, Apr 2nd 11:20 AM
Duration: 30 minutes ®
 Nominate a Mentor, Mentee, or Colleague for a MEDI Award

The Division offers a number of awards to recognize medicinal chemists at various stages of their
careers. Please consider submitting a nomination for one of these awards:

The David W. Robertson Award recognizes young scientists who have made important contributions to
medicinal chemiostry. Nominees must be age 40 or younger at the time of
nomination. Deadline November 1.

The Division of Medicinal Chemistry Award is open to any scientist or team of scientists whose research
has, directly or indirectly, had a significant effect on medicinal chemistry. Deadline November 1.

The Medicinal Chemistry Hall of Fame honors those who have made outstanding contributions to
medicinal chemistry through research, teaching and/or Division service. You can visit the Hall of Fame
at
https://www.acsmedchem.org/?nd=inductees. Deadline May 31.

Follow the links for further information.

Learn more about FastWoRX in ACS Omega at https://pubs.acs.org/doi/10.1021/acsomega.8b00966

Please visit Faster Chemistry at Booth 543 at the ACS National Meeting &
Exposition in Orlando, March 31 – April 2, 2019
 Jointly organised by EFMC, ACSMEDI and the Polish Society of Medicinal Chemistry
Conference topics will include:
• Adding AI to the Drug Discovery Tool Box
• Advances in Protein Degradation Technologies
• Chemical Biology Tools & Target Engagement Technologies
• Genomics in Drug Discovery : Roles for Chemistry
• GPCRs : a Discovery Powerhouse
• Matrix Metallo-Proteinases
• Multi-Targeted Drugs
• Opioid, Pain, Endo-Cannabinoid
• Targeted Covalent Inhibitors

For details: www.medchemfrontiers.org

Orlando: Come to the New, Improved Business Meeting!

The Division bylaws require that MEDI hold an annual Business Meeting. These are usually poorly
attended and rarely conduct any important business (except for the time we considered renaming the
Division!). This year we are transforming the annual Business Meeting into a networking event. Be there!
 Submit Abstracts, Apply For Travel Grants for Fall Meeting in San Diego, CA

You are invited to submit an abstract for a research presentation at the Spring ACS National
Meeting, which will be held August 25-29, 2019, in San Diego. Abstract submission for MEDI sessions is
open now until March 18. To submit your abstract, go to maps.acs.org.
The Division of Medicinal Chemistry makes available a limited number of grants of $1000
annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be
ACS regular or student members, and not have previously received a travel award. To apply for MEDI
student travel grants, go to www.acsmedchem.org/?nd=travelgrants. Deadline for application is the
same as for abstract submission. Awardees will be notified in sufficient time so that they can pre-register
for the meeting. All travel grant recipients are required to acknowledge the Division in a slide or on their
poster as a condition of accepting the award. Awards are made at the Division business meeting,
which is held at each national meeting immediately before the Sunday night poster session and mixer.
Address info and a complete application appears on the website.
Chemical Computing Group is offering student travel grants for student presentations (in oral or
poster format) that include a computational chemistry component. Winners receive $1,150 to offset
their travel expenses, as well as a copy of CCG's MOE (Molecular Operating Environment) software with
a one-year license. Go to www.acsmedchem.org/?nd=ccgawards for details. Deadline for
application is the same as for abstract submission.

The first conference of the Wellcome Centre for Anti-Infectives Research aims to harness cross-
disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate
attrition rates for infectious diseases affecting low and middle income countries. Conference attendees
will take home new ideas and technologies which have been demonstrated to work; applying them to
diseases where challenges to drug discovery are hampering progress.
The conference has been formatted to allow active participation of all conference delegates. Each
session will feature talks from internationally recognised experts followed by a panel discussion providing
the opportunity for the audience to discuss the issues raised with the speakers. There will also be plenty
of networking opportunities through poster sessions and evening social events.
The organising committee encourage researchers working within disease endemic countries to attend
and bring their first-hand knowledge of the impact of infectious diseases to the discussions. 20 travel
bursaries worth up to £1,500 are available to those coming from low and middle income countries to
assist with the costs of attending the conference. Thank you to MMV, DNDi, Novartis BioMedical
Research Institute and the Bill & Melinda Gates Foundation for sponsoring the travel bursaries.
Further information on registration, travel bursaries and abstract submission can be found on the
conference website http://www.lifesci.dundee.ac.uk/research/events/wcair-conference-2019 .
 MEDI Election Results

The Division held its annual election in November. Congratulations to those who were elected,
and our sincere thanks to Dr. Steve Firestine, of Wayne State University, who ran for the Vice Chair
position.
Dr. Scott Runyon was elected Vice Chair for 2019. He will serve a year
as Vice Chair, a year as Chair, and a year as Past Chair. Scott is the Director
of the Center for Drug Discovery at the Research Triangle Institute where he
oversees a team of medicinal and computational chemists as well as
molecular and behavioral pharmacologists. He received his BS in Chemistry
from Muhlenberg College in 1994 and PhD from the Medical College of
Virginia in 2001. He then pursued a post-doctoral fellowship at Research
Triangle Institute under the direction of Dr. F. Ivy Carroll that focused on refining
clinical candidates for the kappa opioid receptor. Since joining RTI in 2001, he
has pursued the development of small molecules for peptidergic G-protein
coupled receptors such as the NPS, APJ, KOR, MAS1, NTR1, ion channels such
as GABAA. More recently, he has worked with collaborators to develop
haptens for use in vaccines against drugs of abuse such as oxycodone and
fentanyl. He served on the MEDI long-range planning committee from 2014-2016.

Dr. Amy Ripka was re-elected Industrial Councilor, for the 2019-2021
term. She has garnered more than 19 years of drug discovery and medicinal
chemistry expertise ranging from big pharma to CROs. At Bristol-Myers Squibb,
Amy was part of the teams that discovered and developed Asunaprevir and
Daclatasvir, for the treatment of Hepatitis C. Later as Head of Chemistry at
EnVivo/FORUM, Amy led the discovery and development of their PDE10
inhibitor into the clinic. She has extensive expertise in drugging GPCRs,
kinases, ion channels, phosphatases, ADCs, and HDACs. Amy has cross-
functional biotech experience in multiple therapeutic areas including
cardiovascular, oncology, pain and CNS having worked at several Boston
biotechs including Infinity, HydraBiosciences, FoldRx and EnVivo/FORUM. Her
work at these companies led to more than 30 issued patents and 5 INDs. Amy was on the Executive
Team at two large life science CROs, Sai Life Sciences in India and WuXiAppTec in China. Most recently
Amy founded Lucy Therapeutics, a Boston-based biotech focused on improving mitochondrial function
for the treatment of neuronal impairment and neurodegenerative diseases.

Dr. Maria-Jesus Blanco was re-elected Industrial Alternate Councilor,

for the 2019-2021 term. Maria is currently Director of Medicinal Chemistry at
Sage Therapeutics in Cambridge, MA since early 2017. Previously, she was
Director of Discovery Chemistry Research & Technologies at Eli Lilly and
member of the Discovery Chemistry management team. She has been
working in medicinal chemistry for nearly 20 years, playing leadership and
strategic roles in Neuroscience as well as emerging fields of drug discovery as
PET ligands, chemical biology, protein-protein interactions and translational
research. Maria was part of the team that discovered Lasmiditan (a selective
5-HT1F compound for migraine treatment currently in phase 3) and
Bevenopran (an opioid antagonist that reached phase 3). Maria obtained her
Bachelor of Science in Chemistry and Ph.D. degree in Synthetic Organic
Chemistry from the University of Santiago de Compostela, Spain. She held
postdoctoral positions at MIT with Prof. Masamune and University of Strasbourg,
France with Nobel Laureate Prof. Sauvage before joining Lilly headquarters in Indianapolis. Maria was
Meeting Co-Chair and Scientific Program Coordinator for the 36th National Medicinal Chemistry
Symposium in Nashville, TN (2018). She is a member of the Editorial Advisory Board of ACS Medicinal
Chemistry Letters.
 2018 Medicinal Chemistry Reviews Now Available To Members

2018 Medicinal Chemistry Reviews (Volume 53) is now available for downloading
from the ACS MEDI Division website (www.acsmedchem.org/). Volume 53 has five
sections devoted to specific therapeutic areas (Central Nervous System Diseases,
Cardiovascular/Metabolic Diseases, Inflammation/Pulmonary/GI Diseases,
Oncology, and Infectious Diseases), two sections covering general topics (Biology
and Drug Discovery/Design), and one section highlighting new chemical entities
(Case Studies for two recently approved compounds, a tabular summary of
compounds entering Phase III in 2017, and the To Market, To Market summary of
compounds achieving first approvals in 2017). The .pdf version is free for ACS MEDI
Division members, so please be sure to take advantage of your membership
benefit.

Instructions for obtaining your copy:

1. Go to www.acsmedchem.org.
2. Click on 'Member Login' near the top right corner.
3. Log in using your ACS login credentials.
4. On your member page, one of the menu bar items is 'Resources.' Under 'Resources' you will see Medicinal
Chemistry Reviews. Select this to get your electronic copy or to order the paperback version.
5. To download the .pdf version, follow the link in the first paragraph.
If you have any problem, please first be sure you are able to log in at www.acs.org. If you can do this and are still
having difficulty, contact the Secretary, secretary@acsmedchem.org.

Director, Medicinal Chemistry

Princeton NJ or Los Angeles, CA
Not for profit research foundation focusing on the discovery and development of therapeutics for the
treatment of Huntington’s Disease
Responsibilities:
Develop a strategic and tactical plan for integrated chemistry projects
Communicate and effectively implement project plan
Manage and influence teams in a matrix and collaborative format
Manage integrated drug discovery teams to efficiently meet team goals
Be able to modify chemistry plan as needed based on weekly scientific data (i.e. SAR)
Resolve chemistry, medicinal chemistry, DMPK issues
Lead and mentor project leaders and medicinal chemists
Resolve potency, selectivity and DMPK issues
Stay on top of all the data for specified project(s)
Clearly articulate the needs of the team and the critical issues of the project to management
Collaborate with internal and external biologist to develop biological tools to help answer key biological questions
Motivate and inspire the team to reach the specified goal(s).
Candidate Profile:
Ph.D. in Organic Chemistry/Medicinal Chemistry
Ten+ years’ experience in pharmaceutical or biotech companies, advancing molecules from hit identification to
clinical trials
Experience with peptide and large molecules characterization & generating labelled molecules for imaging studies
is a plus
Experience in LCMS/MS platforms and evaluating and implementing new technologies
Experience leading a project team from hit identification to phase I clinical trials
Experience in resolving process research issue to enable synthesis of API and phase I clinical trial
Strong understanding of Drug Metabolism and Pharmacokinetics
Ability to understand the basic biology of specified project
Proven problem-solving skills, creativity, and strong publication record
Strong communication skills both oral and written
Please send CV to Alison.khan@chdifoundation.org if interested
 Sponsorship for Division of Medicinal Chemistry Symposia
Division of Medicinal Chemistry symposia at National Meetings are presented in part through the
financial support of sponsor companies. Sponsorship opportunities are available for all upcoming
Division of Medicinal Chemistry Symposia. Symposium sponsors for national ACS meetings are
acknowledged with a prominent sign outside the meeting room, and by session chairs during the
symposium. In addition, a table is provided where company representatives can interact with meeting
attendees, and provide promotional materials. For more information on symposium sponsorship,
contact the 2019-2020 Program Chair, Jacob Schwarz jschwarz@flxbio.com, or the 2018-2020 Division
Treasurer, David Rotella (rotellad@mail.montclair.edu).
The Division would like to thank the generous sponsors of our Boston symposia!

AbbVie
ACS Publications
AstraZeneca
Bristol-Myers Squibb
Chemical Abstracts Service
Gilead
Intellisyn
Janssen
Merck
Pfizer
Sanofi

Mark Your Calendar: 2020 National Medicinal Chemistry Symposium

The 2020 National Medicinal Chemistry Symposium will be held in New York City, Sunday June 28 -
Wednesday July 1, 2020, at the Downtown Marriott Hotel. The organizers are Amjad Ali, Merck
(amjad_ali@merck.com) and Robert Devita, Mount Sinai School of Medicine (robert.devita@mssm.edu).
 Advertise in the ACSMEDI Newsletter
The ACSMEDI Newsletter is distributed twice a year to 9,000 medicinal and organic chemist members,
and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we
have established the following advertising policy:

Full page: $900.00

One-half page: $500.00
One-quarter page: $350.00

To place an ad or obtain more information, contact the editor at eric.walters@rosalindfranklin.edu

Invitation to Authors: Journal of Medicinal Chemistry Perspective Series

The Perspectives series of the Journal of Medicinal Chemistry is designed to provide an enlightened
appraisal of a field of research in which experts review the state-of-the-art for a given area or
therapeutic target. Authors have editorial freedom to express their views on the strategic directions of
the field of research. The Perspectives series provides a forum with high visibility within the
pharmaceutical industry and academia. We would like to identify a wide range of potential topics and
authors to ensure that a Perspectives article is published in every issue of the Journal. We would like the
series to be useful to a broad range of scientists interested in the design, discovery and development of
novel medicines. We invite you to submit an idea for a Perspectives article, along with a brief outline of
what you will cover in the manuscript. We also welcome your input regarding potential topics of interest
and authors for Perspectives manuscripts. Please direct correspondence regarding the series to:
Nicholas Meanwell
Perspectives Editor
Journal of Medicinal Chemistry
meanwell@jmedchem.acs.org
Division Archives Available On-line
Division newsletters, scientific programs and abstract books dating to 2002 are archived online. These
documents can be downloaded in pdf format through the Division WWW page:

http://www.acsmedchem.org
33rd Annual ResMed Course: The Residential School on
Medicinal Chemistry and Biology in Drug Discovery
June 9-14, 2019 Drew University, Madison, NJ
About ResMed:
ResMed is a week-long graduate/professional-
level course providing an accelerated program
for medicinal chemists, biologists and other
industrial and academic scientists who wish to
broaden their knowledge of the drug discovery
and development process. The course
concentrates on the fundamentals of drug
discovery spanning initial target validation
through clinical development.

Topics for 2019 ResMed

Basic Principles of Medicinal Chemistry
Target Identification and Validation
ResMed features lectures and case histories presented by an
Enzyme Inhibition
impressive faculty from a wide range of related disciplines.
Kinase Inhibitors
G-Protein Coupled Receptors
Drugs Affecting Ion Channels
Epigenetic Targets
Bioisosteres
Hit-to-Lead Process in Drug Discovery
Principles of Lead Optimization
Drug-like Properties
Fragment-Based Drug Design
Cheminformatics
Molecular Modeling
Structure-Based Drug Design
Protein Binding
Pharmacokinetics
Drug Metabolism
Improving Drug Candidates by Design
Designing Around Toxicophores
Preclinical Toxicology
Clinical Development
Case History Presentations
ResMed allows attendees the opportunity to speak with expert
lecturers & establish contacts with colleagues globally.

Co-Sponsored by the ACS MEDI Division

CONTACT INFORMATION:
Drew University, ResMed
36 Madison Ave, Hall of Sciences 319
Madison, NJ 07940
(973) 408-4861 | resmed@drew.edu

Register at: www.drew.edu/resmed

Registration includes local hotel accommodations and shuttle service
to/from campus. Reduced registration pricing through March 31, 2019
Environmental Film Competition The ACS Committee on
Environmental
Improvement (CEI)
and the ACS Division of
Environmental Chemistry

PRESENT

2019 Environmental
Film Competition

ACS Fall National

Meeting
San Diego, CA
August 25 – 29, 2019

The American Chemical Society’s Committee on Environmental Improvement

(CEI) and Division of Environmental Chemistry (ENVR) will host an Environ-
mental Film Competition & Showcase at the ACS National Meeting in San Diego,
CA, August 25–29, 2019. The selection committee seeks quality films that are 9-12
minutes focused on environmental issues that provide meaningful, constructive and
encouraging entertainment, while harnessing the transformative power of film.
Finalists will be screened at the showcase during the San Diego meeting.

We encourage filmmakers and scientists to collaborate on projects to get the highest

quality film filled with the most accurate, relevant information.

FILM CRITERIA
The 2019 Fall National Meeting theme is Water; therefore, films focused on the
following themes are invited to apply:
• Water’s effect on land AWARDS AND PRIZES
• Water’s effect on people • "Best Of" for each category for both
• Water’s effect on chemistry student and regular submissions.
• Environmental issues • Cash prizes for four top awards.

For more information please visit:

https://ceifilm.wixsite.com/2019

Entry Due Date: April 30, 2019

 ACS Division of Medicinal Chemistry
Complete Officers/LRPC List 2017

1. Regular Executive Committee Members

Chair 2019 Secretary & Public Relations 2017-2019

Andrew W. Stamford, Ph.D.

Bridge Medicines D. Eric Walters, Ph.D.
Belfer Research Building Department of Pharmaceutical Sciences
413 East 69th Street, Office BB-620 Rosalind Franklin University
New York, NY 10021 3333 Green Bay Road
973-868-2088 North Chicago, IL 60064
astamford@bridgemedicines.com 847-578-8613
eric.walters@rosalindfranklin.edu
Vice Chair 2019
Membership & International Relationships

Scott Runyon, Ph.D.

Research Triangle Institute
3040 Cornwallis Road Daniel A. Harki, Ph.D.
Research Triangle Park, NC 27709 University of Minnesota
919-316-3842 2231 6th Street SE
srunyon@rti.org Minneapolis, MN 55455
612-625-8687
Program Chair 2019-2020 daharki@umn.edu

Treasurer 2018-2020

David P. Rotella, Ph.D.

Jacob Schwarz, Ph.D. Department of Chemistry & Biochemistry
FLX Bio Inc. 355 Richardson Hall
561 Eccles Ave Montclair State University
South San Francisco, CA 94080 Montclair NJ 07043
670-753-1291 (973) 655-7204
jschwarz@flxbio.com rotellad@mail.montclair.edu
Academic Councilor 2017-2019 Industrial Councilor 2019-2021

Jane Aldrich, Ph.D.

Amy Ripka, Ph.D.
Department of Medicinal Chemistry
Lucy Therapeutics
College of Pharmacy
amy@lucytherapeutics.com
University of Florida
P.O. Box 100485
Gainesville, FL 32610-0485 Industrial Councilor 2018-2020
352-273-7714
jaldrich@cop.ufl.edu

Academic Councilor 2018-2020

William J. Greenlee, Ph.D.

MedChem Discovery Consulting, LLC
115 Herrick Avenue
Teaneck, NJ 07666-4106
(908) 463-5332
william@william-greenlee.com

Carrie Haskell-Luevano Past Chair 2019

University of Minnesota College of Pharmacy
308 Harvard Street SE
Minneapolis, MN 55455
(612) 626-9262
chaskell@umn.edu

Paul Ornstein, Ph.D.

Apollo Drug Discovery Consulting
1237 Southwind Drive
Northbrook, IL 60062
317-250-7186
plornstein@apolloddc.com
 2. Alternate Councilors & Other Ad Hoc EC Members

Academic Alternate Councilor 2017-2019 Academic Alternate Councilor

Michael A. Walters, Ph.D. 2018-2020
University of Minnesota Robert J. DeVita, PhD
717 Delaware ST SE, Room 609 Icahn School of Medicine at Mt.
Minneapolis, MN 55414 Sinai
612-626-6864 Drug Discovery Institute
mwalters@umn.edu Dept of Pharmacological
Sciences
One Gustave Levy Place
New York, NY 10029
212-659-5542
robert.devita@mssm.edu

Industrial Alternate Councilor 2019-2020 Industrial Alternate Councilor 2018-2020

Maria-Jesus Blanco, Ph.D. Lori Gavrin, Ph.D.
Sage Therapeutics Tmunity
215 First St, Suite 220 lorikrim@yahoo.com
Cambridge, MA 02142
617-949-4132
maria-
jesus.blanco@sagerx.com

Journal of Medicinal Chemistry Liaison 2019 Editor-in-Chief, Annual Reports in

Gunda Georg, Ph.D. Medicinal Chemistry (2017-2021)
Department of Medicinal Joanne Bronson, Ph.D.
Chemistry Bristol-Myers Squibb
Editor, Journal of Medicinal 5 Research Parkway
Chemistry Wallingford, CT 06422
717 Delaware Street SE 203-677-6431
College of Pharmacy University joanne.bronson@bms.com
of Minnesota Minneapolis, MN
55414
(612)-626-6320
georg@umn.edu
Foreign Societies Liaison 2019
Thomas J. Perun, Ph.D.
Affiliated Scientific
47731 Old Houston Hwy
Hempstead, TX 77445
tjperun@aol.com
 Long Range Planning Committee 2019

LRPC Chair 2019

Kevin S. Currie, Ph.D. (2017-2019)

Scott Runyon, Ph.D.
Gilead Sciences
Research Triangle Institute
199 East Blaine Street
Research Triangle Park, NC 27709
Seattle, WA 98102
919-316-3842
206-454-7100
srunyon@rti.org kevin.currie@gilead.com

Anna K. Mapp, Ph.D. (2017-2019)

University of Michigan
4215 Life Sciences Institute
210 Washtenaw Ave
Ann Arbor, MI 48109
amapp@umich.edu
Jennifer Allen, Ph.D. (2017-2019)
Amgen
Thousand Oaks, CA 91320
805-313-5251
jeallen@amgen.com

Vincent Jo Davisson, Ph.D. (2017-2019)

Purdue University College of Pharmacy
575 Stadium Mall Dr
West Lafayette, IN 47907
Julien Papillon, Ph.D. (2017-2019) 765-494-5238
Novartis Institutes for BioMedical Research davisson@purdue.edu
Cambridge, MA 02139
617-871-7653
julien.papillon@novartis.com

Paul M. Scola Ph.D. (2017-2019)

Senior Principle Scientist
Bristol Myers Squibb Pharmaceutical Institute
Corey Hopkins, Ph.D. (2017-2019) 5 Research Parkway
College of Pharmacy Wallingford, CT 06492
Univ of Nebraska Medical Center Phone (203) 677-7870
Omaha, NE 69198 Paul.Scola@bms.com
402-559-9729
corey.hopkins@unmc.edu

Dan Sutherlin, Ph.D. (2017-2019)
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
650-438-9615
sutherlin.dan@gene.com
Amy Dounay, Ph.D. (2018-2020)
Colorado College
719-389-6438
adounay@coloradocollege.edu
Philip Kym, Ph.D. (2018-2020)
AbbVie
847-935-4699
phil.r.kym@abbvie.com
Terry Moore, Ph.D. (2018-2020)
University of Illinois at Chicago
312-413-1846
twmoore@uic.edu
Jozef Stec, Ph.D. (2018-2020)
Marshall B. Ketchum University
714-872-5711
jstec@ketchum.edu
Erin F. DiMauro, Ph.D. (2019-2021)
Director, Drug Discovery
Merck & Co., Inc.
33 Avenue Louis Pasteur
Boston, MA 02215
617-992-3274
erin.dimauro@merck.com
Damian Young, Ph.D. (2019-2021)
Center for Drug Discovery
Baylor College of Medicine
One Baylor Place
Houston, TX 77030
713-798-5419
damian.young@bcm.edu
Nicole Goodwin, Ph.D. (2019-2021)
GlaxoSmithKline
1250 Collegeville Rd, UP1200
Collegeville, PA 19426
nicole.c.goodwin@gsk.com